Aeterna Zentaris Announces Election of Directors at 2016 Shareholders' Meeting
May 10 2016 - 4:00PM
Business Wire
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the “Company”),
a specialty biopharmaceutical company engaged in developing and
commercializing novel treatments in oncology, endocrinology and
women’s health, today announced the results of the vote on
directors held at its 2016 annual meeting of shareholders held
earlier today on May 10, 2016. Each of the director nominees
proposed by management for election was elected as director,
without a vote by ballot being conducted. The Company received
proxies with regard to voting on the six directors nominated for
election as set forth in the table below:
Name of Nominee Votes For
% Votes Withheld % Michael Cardiff
1,254,909 88.53 162,647 11.47 David A.
Dodd 1,187,024 83.74 230,532 16.26
Carolyn Egbert 1,268,485 89.48 149,071
10.52 Juergen Ernst 1,266,892 89.37
150,664 10.63 Gérard Limoges 1,268,600 89.49
148,956 10.51 Ken Newport 1,254,215
88.48 163,341 11.52
All other matters at the shareholders' meeting were also
approved by shareholders.
About Aeterna Zentaris Inc.
Aeterna Zentaris is a specialty biopharmaceutical company
engaged in developing and commercializing novel treatments in
oncology, endocrinology and women’s health. We are engaged in drug
development activities and in the promotion of products for others.
We are now conducting Phase 3 studies of two internally developed
compounds. The focus of our business development efforts is the
acquisition or license of products that are relevant to our
therapeutic areas of focus. We also intend to license out certain
commercial rights of internally developed products to licensees in
territories where such out-licensing would enable us to ensure
development, registration and launch of our product candidates. Our
goal is to become a growth-oriented specialty biopharmaceutical
company by pursuing successful development and commercialization of
our product portfolio, achieving successful commercial presence and
growth, while consistently delivering value to our shareholders,
employees and the medical providers and patients who will benefit
from our products. For more information, visit www.aezsinc.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160510006447/en/
Aeterna Zentaris Inc.Philip A. TheodoreSenior Vice
President843-900-3223IR@aezsinc.com
Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From Sep 2023 to Sep 2024